A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Algonquin Power & Utilities (NYSE:AQN) said Friday that Rod West will join the company as its new CEO, succeeding Chris ...

West Pharmaceutical Services (NYSE:WST – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday. Other analysts ...

You do it for us.” Shafter added that while he lives in CdN, he told Mayor Mitchell Brownstein and the council that “you are ...

Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, ...

EXTON, Pa. - West Pharmaceutical Services, Inc. (NYSE:WST), a company specializing in solutions for injectable drug ...

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

Fifth Third Bancorp lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 2.0% ...